Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation

• DOI: 10.1016/j.jlr.2021.100092
• Publication Date: 2021-06-17T04:56:11Z
• Authors: Sudip Paul; Adam Alexander T....; Kevin Culham; Kevin A. Gunawan; Jacqueline M. Weir; Michelle A. Cinel; Kaushala S. Jayaw...; Natalie A. Mellett; Man K.S. Lee; Andrew J. Murphy; Graeme I. Lancaster; Paul J. Nestel; Bronwyn A. Kingwell; Peter J. Meikle
• Keywords: Plasmalogen; Dyslipidemia

Plasmalogens are membrane glycerophospholipids with diverse biological functions. Reduced plasmalogen levels have been observed in metabolic diseases; hence, increasing their might be beneficial ameliorating these conditions. Shark liver oil (SLO) is a rich source of alkylglycerols that can metabolized into plasmalogens. This study was designed to evaluate the impact SLO supplementation on endogenous individuals features disease. In this randomized, double-blind, placebo-controlled cross-over study, participants (10 overweight or obese males) received 4-g Alkyrol® (purified SLO) placebo (methylcellulose) per day for 3 weeks followed by 3-week washout phase and were then crossed over alternate placebo/Alkyrol® treatment. led significant changes plasma circulatory white blood cell lipidomes, notably increased plasmalogens other ether lipids. addition, significantly decreased total free cholesterol, triglycerides, C-reactive protein. These findings suggest enrich cellular enrichment may provide protection against obesity-related dyslipidemia inflammation.